Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Blood (2023) 142 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2023-185499

Published: 2023

Journal Articles

Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

Blood (2023) 142 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2023-181833

Published: 2023

Journal Articles

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Blood (2021) 138 (Supplement 1): 3410.

https://doi.org/10.1182/blood-2021-147225

Published: 2021

Journal Articles

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136566

Published: 2020

Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Blood (2019) 134 (Supplement_1): 3943.

https://doi.org/10.1182/blood-2019-128683

Published: 2019

Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 2672.

https://doi.org/10.1182/blood-2018-99-120380

Published: 2018

Journal Articles

Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)

Antonia Beitzen-Heineke, MD, Isabel Ben Batalla, PhD, Nikolaus Berenbrok, Sarina Paesler, Victoria Gensch, Gunhild von Amsberg, Philippe Schafhausen, MD, Kristoffer Riecken, PhD, Thomas Fischer, MD, Klaus Pantel, MD, PhD, Carsten Bokemeyer, MD, PhD, Sonja Loges, MD, PhD

Blood (2018) 132 (Supplement 1): 3063.

https://doi.org/10.1182/blood-2018-99-118175

Published: 2018

Journal Articles

Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis

Janik Engelmann, Isabel Ben Batalla, PhD, Hanna Taipaleenmäki, PhD, Kristoffer Riecken, PhD, Victoria Gensch, Sarina Paesler, Nikolaus Berenbrok, Maria Elena Vargas, Jonas Waizenegger, MD, Boris Fehse, PhD, Klaus Pantel, MD, PhD, Ihab S Darwish, PhD, Somasekhar Bhamidipati, PhD, Esteban Masuda, PhD, Carsten Bokemeyer, MD, PhD, Eric Hesse, MD, PhD, Sonja Loges, MD, PhD

Blood (2018) 132 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2018-99-118273

Published: 2018

Journal Articles

BET-Inhibition By JQ1 Promotes Proliferation and Self-Renewal Capacity of Hematopoietic Stem Cells

Mark Wroblewski, PhD, Marina Scheller-Wendorff, PhD, Raimund Bauer, PhD, Florian Udonta, Jara Schlichting, Lin Zhao, MD, Isabel Ben Batalla, PhD, Victoria Gensch, Marek Wanior, Hanna Taipaleenmäki, PhD, Simona Bolamperti, PhD, Zeynab Najafova, PhD, Klaus Pantel, MD PhD, Carsten Bokemeyer, MD PhD, Eric Hesse, MD PhD, Stefan Knapp, PhD, Steven Johnsen, PhD, Sonja Loges, MD PhD

Blood (2017) 130 (Supplement 1): 1900.

https://doi.org/10.1182/blood.V130.Suppl_1.1900.1900

Published: 2017

Journal Articles

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Sonja Loges, MD PhD, Bjørn Tore Gjertsen, Michael Heuser, MD, Joerg Chromik, Isabel Ben-Batalla, Nuray Akyüz, David Micklem, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1375.

https://doi.org/10.1182/blood.V130.Suppl_1.1375.1375

Published: 2017

Journal Articles

Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia

Monica Hellesøy, PhD, Stein-Erik Gullaksen, Benedicte Sjo Tislevoll, Oda Helen Eck Fagerholt, Hakon Reikvam, MD PhD, Sonja Loges, MD PhD, Jorge Cortes, MD, Michael Heuser, MD, Jörg Chromik, Jørn Skavland, PhD, André Sulen, Øystein Bruserud, MD PhD, Jim Lorens, PhD, Gro Gausdal, PhD, David Micklem, Bjorn T. Gjertsen, MD PhD

Blood (2016) 128 (22): 3995.

https://doi.org/10.1182/blood.V128.22.3995.3995

Published: 2016

Journal Articles

Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324

Monica Hellesøy, PhD, Katarzyna Wnuk-Lipinska, PhD, Anna Boniecka, MSc, Eline Milde Nævdal, Hakon Reikvam, MDPhD, Sonja Loges, MDPhD, Jorge E. Cortes, MD, Jørn Skavland, PhD, Øystein Bruserud, MDPhD, Jim Lorens, PhD, David Micklem, PhD, Gro Gausdal, PhD, Bjorn T. Gjertsen, MD PhD

Blood (2015) 126 (23): 4931.

https://doi.org/10.1182/blood.V126.23.4931.4931

Published: 2015

Journal Articles

BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia

Blood (2015) 126 (23): 1569.

https://doi.org/10.1182/blood.V126.23.1569.1569

Published: 2015

Journal Articles

Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS)

Sarah Krause, Christian Pfeiffer, Susanne Strube, Ameera Alsadeq, Henning Fedders, Christian Vokuhl, Sonja Loges, Jonas Waizenegger, Isabel Ben-Batalla, Gunnar Cario, Anja Möricke, Martin Stanulla, Martin Schrappe, Denis M. Schewe

Blood (2015) 125 (5): 820–830.

https://doi.org/10.1182/blood-2014-06-583062

Published: 2015

Includes: Supplemental data

Journal Articles

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Blood (2014) 124 (21): 4512.

https://doi.org/10.1182/blood.V124.21.4512.4512

Published: 2014

Journal Articles

Expression Of Hedgehog Pathway Mediator Gli2 Represents a Clinically Negative Prognostic Marker In Acute Myeloid Leukemia and Its Inhibitor GANT61 Exerts Anti-Leukemic Effects In Vitro

Jasmin Wellbrock, Ph.D., Julian M Koehler, Katharina Wagner, MD, Emily Latuske, M.Sc., Hauke Stamm, M.Sc., Eik Vettorazzi, M.Sc., Gabi Vohwinkel, M.Sc., Marianne Klokow, Roswitha Kuhling-Thees, Sonja Loges, MD, Ph.D, Michael Amling, MD, Carsten Bokemeyer, MD, Michael Heuser, MD, Juergen Krauter, MD, Walter Fiedler, MD

Blood (2013) 122 (21): 53.

https://doi.org/10.1182/blood.V122.21.53.53

Published: 2013

Journal Articles

Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia

Blood (2013) 122 (21): 1469.

https://doi.org/10.1182/blood.V122.21.1469.1469

Published: 2013

Journal Articles

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

Blood (2013) 122 (14): 2443–2452.

https://doi.org/10.1182/blood-2013-03-491431

Published: 2013

Includes: Supplemental data

Journal Articles

Expression of Gli2, a Downstream Mediator of the Activated Hedgehog Pathway, Represents a Negative Prognostic Marker in AML,

Walter Fiedler, M.D., Gabi Vohwinkel, MSc, Juergen Krauter, MD, Eik Vettorazzi, MSc, Sonja Loges, M.D., Ph.D., Livia Fuhrmann, Patrizia Seyfert, Carsten Bokemeyer, M.D., Jasmin Wellbrock, PhD

Blood (2011) 118 (21): 3535.

https://doi.org/10.1182/blood.V118.21.3535.3535

Published: 2011

Journal Articles

Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia

Alexander Schultze, M.D., M.Sc., Isabel Ben-Batalla, Ph.D., Michael Heuser, M.D., Kristoffer Weber, Ph.D., Robert Erdmann, Ph.D., Sacha Holland, Ph.D., Stefanie Sawall, Helena Fritz, M.Sc., Marc Tjwa, M.D., Ph.D., Thomas Schmidt, M.D., Walter Fiedler, M.D., Boris Fehse, Ph.D., Bjorn Dahlback, M.D., Klaus Pantel, M.D., Ph.D., Jürgen Krauter, Arnold Ganser, MD, Carsten Bokemeyer, M.D., Sonja Loges, M.D., Ph.D.

Blood (2011) 118 (21): 940.

https://doi.org/10.1182/blood.V118.21.940.940

Published: 2011

NARROW

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)

Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis

BET-Inhibition By JQ1 Promotes Proliferation and Self-Renewal Capacity of Hematopoietic Stem Cells

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia

Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324

BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia

Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS)

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Expression Of Hedgehog Pathway Mediator Gli2 Represents a Clinically Negative Prognostic Marker In Acute Myeloid Leukemia and Its Inhibitor GANT61 Exerts Anti-Leukemic Effects In Vitro

Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

Expression of Gli2, a Downstream Mediator of the Activated Hedgehog Pathway, Represents a Negative Prognostic Marker in AML,

Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only